🎙️🎙️🎙️ 𝗪𝗲 𝘀𝘁𝗮𝗿𝘁 𝟮𝟬𝟮𝟮 𝘀𝘄𝗶𝗻𝗴𝗶𝗻𝗴 𝗳𝗿𝗼𝗺 #𝗱𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝘆 to #rheum 𝘄𝗶𝘁𝗵 Vancouver 𝗯𝗮𝘀𝗲𝗱 #rheumatologist and ultrasound aficionado, 𝗗𝗿.Mo Bardi, 𝘄𝗵𝗼 𝘁𝗮𝗸𝗲𝘀 𝘁𝗵𝗲 𝗵𝗲𝗮𝗱𝗮𝗰𝗵𝗲 𝗼𝘂𝘁 𝗼𝗳 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝗻𝗴 𝗮𝗻𝗱 𝗺𝗮𝗻𝗮𝗴𝗶𝗻𝗴 #𝘃𝗮𝘀𝗰𝘂𝗹𝗶𝘁𝗶𝘀 𝗮𝗻𝗱 𝗚𝗶𝗮𝗻𝘁 𝗖𝗲𝗹𝗹 𝗔𝗿𝘁𝗲𝗿𝗶𝘁𝗶𝘀 (𝗚𝗖𝗔).

🔑🔑💡 𝗪𝗵𝗮𝘁 𝘀𝗲𝗰𝗿𝗲𝘁𝘀 𝗱𝗼𝗲𝘀 𝗗𝗿.𝗕𝗮𝗿𝗱𝗶 𝗿𝗲𝘃𝗲𝗮𝗹 𝗮𝗯𝗼𝘂𝘁 𝗵𝗶𝘀 𝗿𝗲𝗳𝗲𝗿𝗿𝗮𝗹𝘀?

😉 𝐘𝐨𝐮 𝐨𝐧𝐥𝐲 𝐥𝐞𝐚𝐫𝐧 𝐭𝐡𝐢𝐬 𝐬𝐭𝐮𝐟𝐟 𝐢𝐟 𝐲𝐨𝐮 𝐰𝐨𝐫𝐤 𝐚𝐥𝐨𝐧𝐠𝐬𝐢𝐝𝐞 𝐃𝐫.Bardi, 𝐨𝐫, 𝐢𝐟 𝐲𝐨𝐮 𝐥𝐢𝐬𝐭𝐞𝐧 𝐭𝐨 𝐭𝐡𝐞 Skin and Joints Podcast. 𝗔𝗻𝗱 𝗼𝗳 𝗰𝗼𝘂𝗿𝘀𝗲 𝘁𝗵𝗲 𝗵𝗶𝗴𝗵-𝘃𝗮𝗹𝘂𝗲 𝗰𝗼𝗻𝘁𝗲𝗻𝘁 𝗰𝗼𝗺𝗲𝘀 𝘄𝗶𝘁𝗵 𝗮 𝗵𝗲𝗮𝗹𝘁𝗵𝘆 𝗱𝗼𝘀𝗲 𝗼𝗳 𝗵𝘂𝗺𝗼𝗿.

🎧🎧 𝐘𝐨𝐮'𝐥𝐥 𝐚𝐥𝐬𝐨 𝐧𝐨𝐭𝐢𝐜𝐞 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐭𝐢𝐦𝐞, 𝐭𝐡𝐞 𝐯𝐨𝐢𝐜𝐞 𝐨𝐟 𝐨𝐮𝐫 #𝐫𝐡𝐞𝐮𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲 𝐟𝐞𝐥𝐥𝐨𝐰 co-host Dr.Ashley Yip! Episode d𝐫𝐨𝐩𝐩𝐢𝐧𝐠 soon. 👇

PART I focuses on the assessment and diagnosis of GCA.

Episode supported by Eli Lilly and Company and Roche.

📻𝘄𝘄𝘄.𝘀𝗸𝗶𝗻𝗮𝗻𝗱𝗷𝗼𝗶𝗻𝘁𝘀.𝗰𝗮

Rheumatologist  | Vancouver

Dr.Mo Bardi completed his training in Internal Medicine and Rheumatology at UBC, including a fellowship in musculoskeletal ultrasound through the American College of Rheumatology USSONAR program.

Further, he has trained internationally in the use of ultrasound for the assessment of large vessel vasculitis and leads a fast-track ultrasound setup in his practice. Dr. Bardi is a Clinical Instructor at the University of British Columbia (UBC) and active rheumatologist staff at Vancouver General Hospital. He is part of the Vasculitis clinic at Mary Pack Arthritis Center with a focus on Giant Cell Arteritis. His ongoing research is in the areas of ultrasound in the assessment of large vessel vasculitis and the diagnostic role of musculoskeletal ultrasound in inflammatory and non-inflammatory joint diseases.

• Evaluate  appropriate  strategies for assessing and diagnosing patients with GCA
• Describe real world clinical pearls for managing patients with GCA and commons differentials

Rate us on Apple Podcasts,  recommend a guest  at [email protected]

📻www.skinandjoints.ca

✉️[email protected]

🎙️🎙️🎙️ 𝐂𝐫𝐨𝐬𝐬𝐢𝐧𝐠 𝐨𝐯𝐞𝐫 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐬𝐤𝐢𝐧 𝐭𝐨 𝐭𝐡𝐞 𝐣𝐨𝐢𝐧𝐭𝐬 𝐚𝐧𝐝 𝐞𝐯𝐞𝐫𝐲𝐭𝐡𝐢𝐧𝐠 𝐢𝐧 𝐛𝐞𝐭𝐰𝐞𝐞𝐧, 𝐰𝐞 𝐜𝐡𝐚𝐭 𝐰𝐢𝐭𝐡 𝐕𝐚𝐧𝐜𝐨𝐮𝐯𝐞𝐫-𝐛𝐚𝐬𝐞𝐝 𝐫𝐡𝐞𝐮𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐢𝐬𝐭, 𝐃𝐫.𝐉𝐨𝐧𝐚𝐭𝐡𝐚𝐧 𝐂𝐡𝐚𝐧, who 𝐭𝐚𝐤𝐞𝐬 𝐮𝐬 𝐨𝐧 𝐚 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐬𝐞𝐜𝐫𝐞𝐭𝐬 𝐌𝐚𝐬𝐭𝐞𝐫𝐂𝐥𝐚𝐬𝐬.

🔑🔑💡 𝐓𝐍𝐅, 𝐈𝐋, 𝐉𝐀𝐊 -𝐰𝐡𝐚𝐭 and how 𝐝𝐨 I 𝐜𝐡𝐨𝐨𝐬𝐞 therapy for PsA?

🎧🎧 It's  a candid conversation where Dr.Chan reveals his psoriatic arthritis PsA clinical secrets ie. the PsA clinical playbook.

We also explore the world of biosimilars, and a one-of-a kind collaborative clinic with Skin and Joints Faculty, Dr.Jan Dutz.

😉 𝐘𝐨𝐮 𝐨𝐧𝐥𝐲 𝐥𝐞𝐚𝐫𝐧 𝐭𝐡𝐢𝐬 𝐬𝐭𝐮𝐟𝐟 𝐢𝐟 𝐲𝐨𝐮 𝐰𝐨𝐫𝐤 𝐚𝐥𝐨𝐧𝐠𝐬𝐢𝐝𝐞 𝐃𝐫.Chan, 𝐨𝐫, of course, 𝐢𝐟 𝐲𝐨𝐮 𝐥𝐢𝐬𝐭𝐞𝐧 𝐭𝐨 𝐭𝐡𝐞 Skin and Joints Podcast.

Email us: [email protected]

Rheumatologist  | Vancouver

 Dr. Chan is an assistant clinical professor at the University of British Columbia and an Adult Rheumatologist and Clinical Investigator with Arthritis Research Canada. (ARC). He has a clinical focus and research interest in the areas of axial spondyloarthritis and psoriatic arthritis. He was awarded an Assessment of Spondyloarthritis Society (ASAS) fellowship grant and completed a clinical fellowship at the University of Toronto in axial spondyloarthritis (ankylosing spondylitis).  Dr.Chan actively pursues research in this field and has been invited to present on this topic internationally in addition to being the coauthor of the Canadian Spondylitis Treatment Guidelines.

His research focuses on early identification, long term outcomes, radiographic progression, and use of administrative databases. Dr.Chan is the core site leader of the  national spondylitis and psoriatic arthritis research cohorts (SPARCC and iPART)  which follow patients with spondyloarthritis and psoriatic arthritis. He also participates in clinical trials evaluating the efficacy and safety of mew therapies in these types of inflammatory arthritis.

• Discuss appropriate  strategies for managing  patients with moderate to severe psoriatic arthritis  (PsA)
• Describe real world clinical  implications and therapy considerations for managing  moderate to severe psoriatic arthritis  (PsA)
• Implement strategies to improve multidisciplinary care coordination between primary care providers and specialty care providers and address the needs of patients with PsA.

*Episode recorded earlier.

Supported by IME grants from TEVA and Bristol Myers Squibb.
www.skinandjoints.ca

📻www.skinandjoints.ca

✉️[email protected]

Dermatologist  | Edmonton

Dr. Jaggi Rao is a double board certified dermatologist (Canada and USA) and a certified cosmetic surgeon. He completed his  dermatology training at the University of Alberta, followed by an accredited fellowship with the American Academy of Cosmetic Surgery in Southern California. Dr. Rao is a full Clinical Professor of Medicine at the University of Alberta. 

Dr. Rao has won several accolades for research and teaching, including the Canadian Dermatology Association’s Teacher of the Year Award.

In 2011, he was the recipient of Avenue Magazine’s Top 40 under 40 Award. He has authored over 50 scientific papers and textbook chapters, and has been an invited speaker for over 500 lectures worldwide to physicians, other professionals, and the general public.

Dr. Rao continues to lend his expertise to various organizations. He sits on the board of directors for CAAM( Canadian Association of Aesthetics  Medicine) and acts as a consultant to the government (such as the Canadian Standards Association), laser and pharmaceutical industry, and professional sports teams.

• Discuss appropriate  strategies for managing  patients with moderate to severe acne and associated psychosocial sequelae  
• Understand  practical real world clinical  implications and key monitoring considerations for managing  severe  inflammatory acne with various formulations of isotretinoin
• Implement strategies to improve multidisciplinary care coordination between primary care providers and specialty care providers and address the needs of patients with acne

Supported by an IME grant from Cipher Pharmaceuticals. 

www.skinandjoints.ca

📻www.skinandjoints.ca

✉️[email protected]

Dermatologist  | Toronto

Dr.Perla Lansang is head of dermatology at Sunnybrook Hospital in Toronto, Ontario and is an assistant professor in the Division of Dermatology, University of Toronto.  She has a special interest in pediatric and adolescent dermatology, having done two years of fellowship in paediatric dermatology at The Hospital for Sick Children. 

At Sunnybrook, she sees general medical dermatology patients and also holds a pregnancy dermatology clinic and also has  a special focus on psoriasis, atopic dermatitis, cutaneous lymphoma, and general medical dermatology. Aside from Sunnybrook Hospital, Dr. Lansang is also affiliated with Women’s College Hospital where she runs a clinic at the Phototherapy Education and Research Centre. She also sees patients at The Hospital for Sick Children, where she has her pediatric dermatology practice.

Dr.Lansang is also a Skin and Joints Podcast Faculty expert.

RESEARCH ARTICLE discussed:

• Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper
• Jensen Yeung, Melinda J. Gooderham, Parbeer Grewal, Chih-ho Hong, Perla Lansang, Kim A. Papp, Yves Poulin, Irina Turchin, Ronald Vender

• Discuss appropriate immunotherapy strategies for women of child bearing potential  with a focus on safety 
• Understand  practical real world clinical  implications for managing moderate to severe plaque psoriasis in women of child bearing potential (WOCBP) pre-partum, pregnancy, and post partum   as well as barriers  and opportunities for implementation 
• Implement strategies to improve multidisciplinary care coordination between primary care providers and specialty care providers and address the needs of patients 

Supported by an IME grant from UCB Canada.

www.skinandjoints.ca

A big thank you to  the thousands of healthcare providers. specialists, and primary care providers, signed up and engaged with the Skin and Joints podcast from across the country!

📻www.skinandjoints.ca

✉️[email protected]

Dermatologist and Rheumatologist | Vancouver

We're going to talk to a practice expert who literally can provide a perspective from both a rheumatology and dermatology point of view.

Dr. Jan Dutz is a professor of medicine and the current head of dermatology  at the university of British Columbia. . He is a Senior Scientist with the Child and Family Research Institute (CFRI) where his research focus is the skin immune system and the manipulation of this system to both promote immune responses and induce tolerance.

Dr.Dutz is one of the few physicians in North America to be board certified and maintain active practice in both rheumatology and dermatology. And  he is a Senior Scientist with the Child and Family Research Institute (CFRI) where his research focus is the skin immune system and the manipulation of this system to both promote immune responses and induce tolerance.

• Discuss appropriate screening strategies for patients with moderate to severe psoriasis suspected of psoriatic arthritis and the patient journey
• Understand current evidence  and practical real world clinical  implications for validated PsA screening tools as well as barriers  and opportunities for implementation 
• Implement strategies to improve multidisciplinary care coordination between primary care providers and specialty care providers and address the needs of patients 

NATIONAL PSORIASIS FOUNDATION Psoriatic Arthritis Screening Tool for Providers 

• Available from: https://www.psoriasis.org/psoriatic-arthritis-screening-tool-for-providers/

RESEARCH ARTICLE

Psoriatic arthritis screening: A systematic literature review and experts’ recommendations

• Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0248571

Disclaimer: This is an educational podcast only and does not replace professional medical advice. Please consult your healthcare provider for any health issues.

Supported by an IME grant from NOVARTIS.

www.skinandjoints.ca

📻www.skinandjoints.ca

✉️[email protected]

• Discuss appropriate assessment strategies for disease activity and prognosis to guide treatment decisions for moderate to severe plaque psoriasis, Including primary and secondary treatment failures  in patients 
• Understand the role  current evidence  and real world clinical  guidance to make effective individualized treatment decisions for patients with refractory moderate to severe PsO, specifically exploring the role of brodalumab
• Implement strategies to improve interprofessional care coordination between primary care providers and specialty care providers and address the needs of patients 

Dermatologist, Montreal

Dr. Elena Netchiporouk is an Assistant Professor and Director of Undergraduate Medical Education in Dermatology at McGill University. She earned her M.D. degree at Université de Montréal and dermatology residency training at the McGill University Health Centre with an Experimental Medicine M.Sc. degree from McGill University.

Elena is a Junior Scientist within the Infectious Diseases and Immunity in Global Health Program of the MUHC-Research Institute studying cutaneous autoimmunity, scleroderma and chronic urticaria. She leads a complex care, skin fibrosis and chronic urticaria clinics at the Montreal General Hospital Site of the MUHC.

Her research program is supported by several grants from the Canadian Dermatology Foundation, Association des Médecins Spécialistes Dermatologues du Québec, Department of Medicine (McGill University) and Ministère d’Éducation et Innovation du Québec. She is actively involved in Dermatology Residency Training Program and is the founder of the Interactive Dermatology Learning Platform for Dermatology residents and Primary Care Providers Montreal Derm FilEZ© (Montrealdermfilez.ca) set to launch this year. 

Disclaimer: This is an educational podcast only and does not replace professional medical advice. Please consult your healthcare provider for any health issues.

Supported by an IME grant from Bausch Health.

www.skinandjoints.ca

📻www.skinandjoints.ca

✉️[email protected]

Episode Learning Objectives 

· Explore  assessment strategies  based on  disease activity  to guide treatment decisions for moderate to severe atopic dermatitis

· Apply current evidence as well as shared decision-making to  individualize therapy decisions for patients with moderate to severe atopic dermatitis; specifically real world experience around dupilumab (DUPIXENT) and a recent publication exploring  upadacitinib (RINVOQ), an experimental indication for AD vs dupilumab

· Implement strategies to improve interprofessional care coordination between primary care providers and specialty care providers and address the unmet needs of patients

ABOUT DR.ASHLEY O'TOOLE, MHSc, MD, FRCPC:

Dr. O’Toole is a dermatologist with the SKiN Centre for Dermatology in Peterborough, Ontario where she also serves as a sub-investigator for multiple clinical trials. She is an adjunctive professor at Queens University and involved in teaching medical students and residents and holds medical privileges at the Peterborough Regional Health Centre. 

After receiving a Master’s of Health Science in Health and Behavioural Communication at Ryerson University in Toronto, Ontario, Dr. O’Toole received her medical degree from McMaster University in Hamilton, Ontario, and completed her residency in dermatology at the University of Ottawa in Ottawa, Ontario. 

Dr. O’Toole is the author or co-author of over 20 peer-reviewed publications and has been involved ias a sub-investigator for over 40 clinical trials on atopic dermatitis, psoriasis, alopecia, acne and vitiligo.

Disclaimer: This is an educational podcast only and does not replace professional medical advice. Please consult your healthcare provider for any health issues.

Discussed:

• HEADS UP Trial: https://jamanetwork.com/journals/jamadermatology/fullarticle/2782803
• Real-world experience of dupilumab in the treatment of moderate-to-severe atopic dermatitis: https://onlinelibrary.wiley.com/doi/full/10.1111/ijd.15053

 Supported by IMEs from  Janssen and Lilly 

www.skinandjoints.ca

📻www.skinandjoints.ca

✉️[email protected]

Episode Learning Objectives

• Discuss appropriate assessment strategies for disease activity and prognosis to guide treatment decisions for moderate to severe plaque psoriasis
• Apply current evidence and guidelines on targeted biologics with shared decision-making to make effective individualized treatment decisions for patients with moderate-to-severe plaque PsO (specifically ixekizumab and Guselkumab)
• Implement evidence-based and expert consensus strategies to improve interprofessional care coordination and address the needs of patients with comorbidities

ABOUT DR.CHRISTINA HAN, MD, FRCPC:

Dr. Christina Han is a dermatologist practicing medical and surgical dermatology in Vancouver, BC and is certified to practice in both the United States and Canada. She sees a broad range of dermatology patients, including pediatric and adults and focuses her practice on medical dermatology. Her clinical focus includes inflammatory conditions, including psoriasis, atopic dermatitis, and acne. She also teaches medical students and residents and is a Clinical Assistant Professor with the Department of Dermatology at UBC. 

Disclaimer: This is an educational podcast only and does not replace professional medical advice. Please consult your healthcare provider for any health issues.

Supported by IMEs from  Janssen and Lilly 

www.skinandjoints.ca

📻www.skinandjoints.ca

✉️[email protected]